Blood Products Advisory Committee
This article was originally published in The Gray Sheet
Standard testing for human immunodeficiency virus variants is among the topics planned for discussion by the panel at a June 19 meeting in Rockville, Maryland. For additional information, contact Linda Smallwood at 301/827-3514 or FDA's information line at 800/741-8131 and use code 19516...
You may also be interested in...
Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.